• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Achieve Life Sciences Inc. (Amendment)

    3/23/23 4:45:46 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ACHV alert in real time by email
    SC 13D/A 1 sc13da207609011_03232023.htm AMENDMENT NO. 2 TO THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 2)1

    ACHIEVE LIFE SCIENCES, INC.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    004468500

    (CUSIP Number)

    DIALECTIC CAPITAL MANAGEMENT, LP

    119 Rowayton Avenue, 2nd Floor

    Norwalk, Connecticut 06853

    (212) 230-3232

     

    ANDREW FREEDMAN, ESQ.

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    March 21, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☒.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 004468500

      1   NAME OF REPORTING PERSON  
             
            Dialectic Capital Management, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☒
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,494,000  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              3,494,000  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,494,000  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            19.5%  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 004468500

      1   NAME OF REPORTING PERSON  
             
            Dialectic Partners, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☒
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,494,000  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              3,494,000  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,494,000  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            19.5%  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 004468500

     

      1   NAME OF REPORTING PERSON  
             
            Dialectic Life Sciences SPV LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☒
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,494,000  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              3,494,000  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,494,000  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            19.5%  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    4

    CUSIP No. 004468500

     

      1   NAME OF REPORTING PERSON  
             
            Dialectic LS Manager LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☒
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,494,000  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              3,494,000  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,494,000  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            19.5%  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    5

    CUSIP No. 004468500

     

      1   NAME OF REPORTING PERSON  
             
            John Fichthorn  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☒
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            PF; OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         55,000  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,494,000  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              55,000  
        10   SHARED DISPOSITIVE POWER  
               
              3,494,000  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,549,000  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            19.8%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    6

    CUSIP No. 004468500

    The following constitutes Amendment No 2 (this “Amendment No. 2”) to the Schedule 13D filed by the undersigned. This Amendment No. 2 amends the Schedule 13D as specifically set forth herein.

     

    Item 4.Purpose of Transaction.

    Item 4 is hereby amended to add the following:

     

    On March 21, 2023, the Reporting Persons entered into an amendment (the “Amendment”) to its Cooperation Agreement with the Issuer regarding certain changes to the composition of the Board and other related matters.

     

    Pursuant to the terms of the Amendment, the Company shall, no later than April 3, 2023, appoint the Designees to the Board to fill three vacancies created by either (x) the departure of the Incumbent Directors or (y) expanding the Board size to up to 11 directors.

     

    The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment filed as 99.1 hereto.

     

    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 is hereby amended to add the following:

    On March 21, 2023, the Reporting Persons and the Issuer entered into the Amendment as defined and described in Item 4 above and attached as Exhibit 99.1 hereto.

    Other than as described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

    Item 7.Material to be Filed as Exhibits.
    99.1Amendment to the Cooperation Agreement, dated March 21, 2023, by and among Achieve Life Sciences, Inc., Dialectic Capital Management, LP and the other parties set forth on the signature pages thereto

    7

    CUSIP No. 004468500

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: March 23, 2023

     

     

    Dialectical Capital Management, LP

    Dialectic Partners, LLC

    Dialectic Life Sciences SPV LLC

    Dialectic LS Manager LLC

    John Fichthorn

       
      By:

    /s/ John Fichthorn

        Name: John Fichthorn
        Title: Authorized Signatory

     

    8

    Get the next $ACHV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHV

    DatePrice TargetRatingAnalyst
    4/21/2026$13.00Buy
    Canaccord Genuity
    11/25/2025$19.00Mkt Outperform
    Citizens JMP
    8/21/2025$12.00Buy
    H.C. Wainwright
    11/14/2024$12.00Buy
    Rodman & Renshaw
    9/27/2024$20.00Strong Buy
    Raymond James
    5/10/2023$8.00 → $20.00Buy
    Maxim Group
    10/4/2021$25.00Buy
    Alliance Global Partners
    6/23/2021$23.00Outperform
    Oppenheimer
    More analyst ratings

    $ACHV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Waldman Reid Alexander

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    6/2/26 4:13:36 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Director Farrow Jeffrey S

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    6/2/26 4:12:33 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Waldman Reid Alexander claimed no ownership of stock in the company (SEC Form 3)

    3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    6/2/26 4:11:26 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    SEC Filings

    View All

    Achieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update

    8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

    6/2/26 8:51:39 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form PRE 14A filed by Achieve Life Sciences Inc.

    PRE 14A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

    5/29/26 4:15:43 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form EFFECT filed by Achieve Life Sciences Inc.

    EFFECT - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

    5/22/26 12:15:16 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ACHV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ACHV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

    SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Jeffrey Farrow and Reid Waldman, MD have been appointed to its Board of Directors. "Jeffrey and Reid are exactly the kinds of operators you want around a board table when a company is preparing for its first launch," said Lucian Iancovici, MD, incoming Chairman of the Board of Directors of Achieve. "Jeffrey has lived the playbook of taking specialty companies from lat

    6/2/26 8:30:00 AM ET
    $ACHV
    $MANE
    $TARS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

    ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous exposure Nausea — a common barrier to treatment adherence with smoking cessation therapies — was reported in only 2.5% of participants over 52 weeks of continuous exposure¹ SEATTLE and VANCOUVER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today

    5/19/26 2:15:00 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

    SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced three senior leadership appointments. Christopher Martin has joined the Company's Board of Directors. Mark Zappia has joined as Senior Vice President, Commercial, where he will spearhead the Company's commercial function. Jim Willis has joined as Vice President of Sales and Sales Enablement, where he will lead the field force. Mr. Martin most recently served as Chief Commercia

    5/12/26 7:05:00 AM ET
    $ACHV
    $EWTX
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Canaccord Genuity initiated coverage on Achieve Life Sciences with a new price target

    Canaccord Genuity initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $13.00

    4/21/26 7:30:27 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Citizens JMP initiated coverage on Achieve Life Sciences with a new price target

    Citizens JMP initiated coverage of Achieve Life Sciences with a rating of Mkt Outperform and set a new price target of $19.00

    11/25/25 8:38:19 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    H.C. Wainwright initiated coverage on Achieve Life Sciences with a new price target

    H.C. Wainwright initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $12.00

    8/21/25 8:16:03 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Oki Mark K bought $28,887 worth of shares (10,000 units at $2.89) (SEC Form 4)

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    3/19/25 4:38:43 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chieve Executive Officer Stewart Richard Alistair bought $28,598 worth of shares (10,000 units at $2.86), increasing direct ownership by 20% to 60,876 units (SEC Form 4)

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    3/19/25 4:32:22 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Stewart Richard Alistair bought $45,850 worth of shares (10,000 units at $4.58), increasing direct ownership by 35% to 38,501 units (SEC Form 4)

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    3/6/24 4:49:23 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Leadership Updates

    Live Leadership Updates

    View All

    Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

    Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors  New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone Warrants), Strengthen Achieve's Position to Execute Development and Launch of Cytisinicline, if Approved, as the First New Treatment for Nicotine Dependence in Two Decades SEATTLE and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) today announced it has appointed Andrew D. Goldberg, MD, as Chief Executive Officer and as a member of the Board of Directors, effective following the closing of Achieve's recently announced financing

    4/16/26 8:57:06 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Announces Up to $354 Million Private Placement

    $180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace SEATTLE, Wash. and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities for

    4/16/26 8:53:49 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

    SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) --  Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the appointment of Erik Atkisson as Chief Legal Officer. In his new role, Mr. Atkisson will oversee Achieve's legal strategy, corporate governance, compliance, and risk management. "Erik's extensive legal, regulatory and M&A background in the biopharmaceutical sector provides valuable experience as we advance cytisinicline through regulatory review and prepare for a potential laun

    10/20/25 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Financials

    Live finance-specific insights

    View All

    Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

    Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U.S.-based Manufacturing Transition & Partnership Conference Call Scheduled for 8:30 AM EDT Today, May 12, 2026 SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced financial results for the first quarter of 2026 and provided corporate highlights

    5/12/26 7:00:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026

    SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its first quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q26 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or +1 201-689-7817 (International) and referencing conference ID 13759781. A webcast replay will be avail

    5/5/26 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced financial results for the fourth quarter and full year 2025 and provided updates on the cytisinicline development program, including the announcement of its partnership with Adare Pharma Solutions (Adare). "Achieve is full

    3/24/26 7:00:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Achieve Life Sciences Inc.

    SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

    11/12/24 12:14:09 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Achieve Life Sciences Inc.

    SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

    11/4/24 10:59:37 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Achieve Life Sciences Inc. (Amendment)

    SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

    5/20/24 5:01:27 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care